HC Wainwright Issues Negative Estimate for Cibus Earnings

Cibus, Inc. (NASDAQ:CBUS) – HC Wainwright reduced their Q4 2024 earnings estimates for shares of Cibus in a research note issued on Monday, November 11th. HC Wainwright analyst A. Dayal now anticipates that the company will earn ($1.00) per share for the quarter, down from their prior forecast of ($0.96). HC Wainwright currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for Cibus’ current full-year earnings is ($3.84) per share. HC Wainwright also issued estimates for Cibus’ FY2025 earnings at ($3.38) EPS, FY2026 earnings at ($3.16) EPS, FY2027 earnings at ($2.39) EPS and FY2028 earnings at ($1.05) EPS.

Other equities analysts have also issued research reports about the stock. Canaccord Genuity Group upgraded shares of Cibus to a “strong-buy” rating in a report on Friday, July 19th. Alliance Global Partners decreased their target price on Cibus from $25.00 to $23.50 and set a “buy” rating for the company in a research report on Tuesday, September 24th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $20.00 target price on shares of Cibus in a report on Tuesday, October 22nd.

Cibus Stock Performance

NASDAQ CBUS opened at $5.31 on Wednesday. The firm has a market capitalization of $122.61 million, a price-to-earnings ratio of -0.26 and a beta of 1.79. Cibus has a one year low of $2.86 and a one year high of $23.18. The company’s 50 day moving average price is $4.06 and its 200 day moving average price is $8.68.

Hedge Funds Weigh In On Cibus

Institutional investors and hedge funds have recently made changes to their positions in the business. SG Americas Securities LLC acquired a new stake in Cibus in the third quarter valued at $33,000. Charles Schwab Investment Management Inc. increased its position in shares of Cibus by 14.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 49,285 shares of the company’s stock worth $161,000 after purchasing an additional 6,276 shares during the last quarter. FineMark National Bank & Trust raised its stake in shares of Cibus by 24.3% in the 2nd quarter. FineMark National Bank & Trust now owns 20,488 shares of the company’s stock valued at $202,000 after purchasing an additional 4,000 shares in the last quarter. Squarepoint Ops LLC bought a new position in shares of Cibus during the second quarter worth about $214,000. Finally, Rhumbline Advisers acquired a new position in Cibus in the second quarter worth about $221,000. 33.81% of the stock is currently owned by hedge funds and other institutional investors.

Cibus Company Profile

Cibus, Inc, a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases.